We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+32.58%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$476M
Cap. Flow
+$118M
Cap. Flow %
5.96%
Top 10 Hldgs %
48.1%
Holding
113
New
18
Increased
27
Reduced
34
Closed
25

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$62.7M
2
ELV icon
Elevance Health
ELV
+$59M
3
TGTX icon
TG Therapeutics
TGTX
+$52.7M
4
TWST icon
Twist Bioscience
TWST
+$45.8M
5
NVCR icon
NovoCure
NVCR
+$36.6M

Top Sells

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$73.4M
2
STAA icon
STAAR Surgical
STAA
+$59.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$37.3M
4
GRFS
Grifois
GRFS
+$32.5M
5
URGN icon
UroGen Pharma
URGN
+$27M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.61B
$22.4M 1.13%
2,422,833
– –
IART icon
27
Integra LifeSciences
IART
$1.38B
$20.6M 1.04%
1,440,818
+53,000
+4% +$726K
NBIX icon
28
Neurocrine Biosciences
NBIX
$16.4B
$19.4M 0.98%
+138,000
New +$18.7M
ANAB icon
29
AnaptysBio
ANAB
$1.63B
$19.2M 0.97%
626,040
+305,000
+95% +$7M
FOCL
30
EDAP TMS S.A.
FOCL
$228M
$16.7M 0.84%
7,309,254
– –
PHVS icon
31
Pharvaris
PHVS
$2.34B
$16.1M 0.81%
647,052
-85,916
-12% -$1.91M
VCEL icon
32
Vericel Corp
VCEL
$2.32B
$15.7M 0.79%
497,953
+447,000
+877% +$16.1M
CCCC icon
33
C4 Therapeutics
CCCC
$400M
$15.7M 0.79%
7,053,942
+75,000
+1% +$180K
BLTE
34
Belite Bio
BLTE
$6.35B
$15.5M 0.78%
+210,000
New +$13.8M
VCYT icon
35
Veracyte
VCYT
$3.71B
$14.5M 0.73%
422,055
-293,384
-41% -$8.42M
RAPT
36
DELISTED
RAPT Therapeutics
RAPT
$13.9M 0.7%
+537,903
New +$7.04M
URGN icon
37
UroGen Pharma
URGN
$2.26B
$13.5M 0.68%
679,000
-1,506,000
-69% -$27M
STAA icon
38
STAAR Surgical
STAA
$1.14B
$13.4M 0.68%
500,000
-2,484,733
-83% -$59.2M
SION
39
Sionna Therapeutics
SION
$2.14B
$12.2M 0.61%
413,500
+37,500
+10% +$816K
CGON icon
40
CG Oncology
CGON
$6.39B
$11.7M 0.59%
290,000
+135,000
+87% +$3.92M
QURE icon
41
uniQure
QURE
$3.07B
$11.7M 0.59%
+200,000
New +$3.63M
QDEL icon
42
QuidelOrtho
QDEL
$1.19B
$11M 0.56%
375,000
+201,000
+116% +$5.5M
MIRM icon
43
Mirum Pharmaceuticals
MIRM
$6.45B
$10.9M 0.55%
148,696
-150,000
-50% -$9.54M
ADMA icon
44
ADMA Biologics
ADMA
$2.15B
$10.8M 0.54%
738,000
+563,000
+322% +$9.65M
IKT icon
45
Inhibikase Therapeutics
IKT
$377M
$10.2M 0.52%
6,325,000
– –
GMED icon
46
Globus Medical
GMED
$10.9B
$10.1M 0.51%
+176,000
New +$10.1M
GSK icon
47
GSK
GSK
$103B
$9.5M 0.48%
+220,000
New +$8.59M
RIGL icon
48
Rigel Pharmaceuticals
RIGL
$749M
$9.35M 0.47%
330,010
-328,135
-50% -$9.82M
EOLS icon
49
Evolus
EOLS
$407M
$8.9M 0.45%
1,450,000
-669,000
-32% -$5.22M
VSTM icon
50
Verastem
VSTM
$516M
$8.26M 0.42%
935,909
– –
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Soleus Capital Management held 113 positions worth $1.99B, up 32% from $1.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Soleus Capital Management deployed $118M of net new capital in Q3 2025, opening 18 new positions and adding to 27 existing holdings. Its largest new stake was Amicus Therapeutics: 4,690,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Celcuity, an estimated $73.4M trimmed.

  • Soleus Capital Management's largest Q3 2025 buy was Amicus Therapeutics: 4,690,000 shares worth $37M.
  • Soleus Capital Management added most to Inspire Medical Systems in Q3 2025, an estimated $62.7M increase.
  • Soleus Capital Management's biggest Q3 2025 reduction was Celcuity, cutting an estimated $73.4M.
  • Soleus Capital Management fully exited UnitedHealth in Q3 2025, selling an estimated $26.9M.
  • Soleus Capital Management's ten largest holdings make up 48% of its $1.99B portfolio in Q3 2025.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q3 2025.
  • Soleus Capital Management's portfolio value rose 32% quarter-over-quarter to $1.99B.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.